Evidence map›Paper›PMID 40411310›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Kidney function and cognitive aging and impairment among diverse Hispanic/Latino individuals: Study of Latinos-Investigation of Neurocognitive Aging (HCHS/SOL).

Hector M González, Sayaka Kuwayama, Natasha Anita, Douglas Galasko, Freddie Márquez, Ariana M Stickel, Martha Daviglus, Tali Elfassy, Tanya Johns, James Lash and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hector M GonzálezDepartment of Neurosciences and the Shiley-Marcos Alzheimer's Disease Research Center, UC San Diego, La Jolla, California, USA.ORCID 0000-0003-4867-7902
Sayaka KuwayamaDepartment of Neurosciences and the Shiley-Marcos Alzheimer's Disease Research Center, UC San Diego, La Jolla, California, USA.
Natasha AnitaDepartment of Neurosciences and the Shiley-Marcos Alzheimer's Disease Research Center, UC San Diego, La Jolla, California, USA.
Douglas GalaskoDepartment of Neurosciences and the Shiley-Marcos Alzheimer's Disease Research Center, UC San Diego, La Jolla, California, USA.
Freddie MárquezDepartment of Neurosciences and the Shiley-Marcos Alzheimer's Disease Research Center, UC San Diego, La Jolla, California, USA.
Ariana M StickelDepartment of Psychology, San Diego State University, San Diego, California, USA.
Martha DaviglusInstitute for Minority Health Research, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA.
Tali ElfassyDepartment of Medicine, University of Miami, Miami, Florida, USA.
Tanya JohnsAlbert Einstein, College of Medicine, Division of Nephrology, Bronx, New York, USA.
James LashInstitute for Minority Health Research, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA.
Nora FranceschiniGillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Wassim TarrafInstitute of Gerontology & Department of Healthcare Sciences, Wayne State University, Detroit, Michigan, USA.

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAMES B BREWER · 2019 to 2026
$34.9M
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's diseaseR01AG075758 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Charles DeCarli, Hector M Gonzalez · 2022 to 2026
$21.7M
Study of Latinos Investigation of Neurocognitive Aging 2R56AG048642 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DECARLI, CHARLES, GONZALEZ, HECTOR M · 2020 to 2021
$8.7M
Neurocognitive aging, MCI and Alzheimer's disease DNA methylation among diverse LatinosRF1AG061022 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FORNAGE, MYRIAM, GONZALEZ, HECTOR M · 2019 to 2019
$6.6M
UCSD Leading the Advancement of Underrepresented Neuroscientists for Change (LAUNCH) Faculty Development ProgramR25NS117367 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victoria B Risbrough, Joann Trejo · 2020 to 2026
$1.6M
Risk Factors for Alzheimer's Disease Among Latinos: Relationships Between Cardiovascular Disease Risk, Acculturation, Small Vessel Disease, and Alzheimer's BiomarkersK08AG075351 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ariana Stickel · 2022 to 2026
$770k
Albert Einstein College of Medicine HHSN268201300002IAlbert Einstein College of Medicine N01-HC-65235Hispanic Community Health StudyNHGRI NIH HHS HHSN268201300003CNHLBI NIH HHS HHSN268201300001CNHLBI NIH HHS HHSN268201300003INHLBI NIH HHS HHSN268201300004CNHLBI NIH HHS HHSN268201300005CNIA NIH HHS K08 AG075351NIA NIH HHS P30 AG062429NIA NIH HHS P30AG062429NIA NIH HHS R01 AG075758NIA NIH HHS R01AG075758NIA NIH HHS R56 AG048642NIA NIH HHS R56AG048642NIA NIH HHS RF1 AG061022NIA NIH HHS RF1AG061022NIDCD NIH HHSNIDCR NIH HHSNIDDK NIH HHSNIMHD NIH HHSNINDS NIH HHS R25 NS117367San Diego State University HHSN268201300005ISan Diego State University N01-HC-65237University of Illinois at Chicago N01-HC-65236University of Miami HHSN268201300004IUniversity of Miami N01-HC-65234University of North Carolina HHSN268201300001IUniversity of North Carolina N01-HC-65233
6 · The paper itself

Abstract

introductionThe purpose of this study is to examine associations between kidney disease and cognitive impairment among diverse middle-aged and older Hispanic/Latino individuals.

methodsBetween 2016 and 2018, the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) enrolled diverse Hispanic/Latino individuals ages 50 years and older (n = 6377). Cognitive function, cognitive change, and mild cognitive impairment (MCI) were the primary outcomes. Chronic kidney disease (CKD, defined as estimated glomerular filtration rate [eGFR] < 60 mL/min per 1.73 m2 or urine albumin-creatinine ratio [uACR] ≥ 30 mg/g) and two independent secondary exposures (i.e., eGFR and uACR) were examined.

resultsCKD was associated with lower cognitive function and 7-year cognitive decline independent of diabetes and hypertension. CKD was associated with MCI, but the effect attenuated by adjustments for CVD risk factors. More albuminuria was associated with lower cognitive function, cognitive decline, independent of CVD risk factors. DISCUSSION: CKD and higher albuminuria were linked to lower cognitive function, cognitive decline, and elevated risk for MCI among diverse middle-aged and older Hispanic/Latino individuals. HIGHLIGHTS: Kidney disease has garnered increased attention in interpreting blood-based biomarkers of Alzheimer's disease and related disorders. Hispanic/Latino individuals are at increased risk for kidney disease. We found that urinary albumin-to-creatinine ratio outperformed estimated glomerular filtration in relation to cognitive function and impairment. Our findings suggest that kidney dysfunction is an independent marker of cognitive function and impairment.

Indexed as

AlbuminuriaCognitive AgingCognitive DysfunctionHispanic or LatinoRenal Insufficiency, ChronicAgedCreatinineFemaleGlomerular Filtration RateHumansMaleMiddle AgedRisk FactorsCreatinineAlzheimer's diseasechronic kidney diseaseCKDcognitive agingdementiaHispanic/LatinokidneyMCIMild cognitive impairmentrenal

Identifiers

PMID40411310
PMCPMC12102662

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.